Here are the 10-K annual reports from Curis Inc (CRIS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CRIS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRIS filings page.
Curis, Inc. is a biotechnology company focused almost entirely on developing emavusertib (CA-4948), an oral IRAK4/FLT3 inhibitor for hematologic cancers including PCNSL, CLL and AML. Emavusertib has Orphan Drug Designation in the U.S. for PCNSL, AML and MDS, and in Europe for PCNSL.
The company highlights substantial financial strain. As of December 31, 2025, it held $5.1 million in cash and cash equivalents and subsequently raised about $18.6 million net in a January 2026 PIPE financing. Management states there is substantial doubt about Curis’s ability to continue as a going concern and that significant additional capital will be required to fund development and operations.
Curis may need equity financings, collaborations or strategic alternatives, including asset sales or a sale of the company, and acknowledges potential outcomes such as dissolution or bankruptcy if funding cannot be secured. In November 2025, it sold its Erivedge royalty entity, ending revenue from the Genentech collaboration. As of March 20, 2026, there were 39,978,693 common shares outstanding, and Curis also notes the risk of Nasdaq delisting if listing standards are not maintained.